Hepatitis B

Επιστημονική δημοσίευση - Άρθρο Περιοδικού uoadl:3339292 36 Αναγνώσεις

Μονάδα:
Ερευνητικό υλικό ΕΚΠΑ
Τίτλος:
Hepatitis B
Γλώσσες Τεκμηρίου:
Αγγλικά
Περίληψη:
Hepatitis B virus (HBV) infection is a major public health problem, with an estimated 296 million people chronically infected and 820 000 deaths worldwide in 2019. Diagnosis of HBV infection requires serological testing for HBsAg and for acute infection additional testing for IgM hepatitis B core antibody (IgM anti-HBc, for the window period when neither HBsAg nor anti-HBs is detected). Assessment of HBV replication status to guide treatment decisions involves testing for HBV DNA, whereas assessment of liver disease activity and staging is mainly based on aminotransferases, platelet count, and elastography. Universal infant immunisation, including birth dose vaccination is the most effective means to prevent chronic HBV infection. Two vaccines with improved immunogenicity have recently been approved for adults in the USA and EU, with availability expected to expand. Current therapies, pegylated interferon, and nucleos(t)ide analogues can prevent development of cirrhosis and hepatocellular carcinoma, but do not eradicate the virus and rarely clear HBsAg. Treatment is recommended for patients with cirrhosis or with high HBV DNA levels and active or advanced liver disease. New antiviral and immunomodulatory therapies aiming to achieve functional cure (ie, clearance of HBsAg) are in clinical development. Improved vaccination coverage, increased screening, diagnosis and linkage to care, development of curative therapies, and removal of stigma are important in achieving WHO's goal of eliminating HBV infection by 2030. © 2023 Elsevier Ltd
Έτος δημοσίευσης:
2023
Συγγραφείς:
Jeng, W.-J.
Papatheodoridis, G.V.
Lok, A.S.F.
Περιοδικό:
The Lancet Neurology
Εκδότης:
Elsevier B.V.
Τόμος:
401
Αριθμός / τεύχος:
10381
Σελίδες:
1039-1052
Λέξεις-κλειδιά:
bulevirtide; entecavir; hepatitis B antibody; hepatitis B surface antigen; hepatitis B vaccine; peginterferon alpha; prehevbrio; tenofovir alafenamide; tenofovir disoproxil; virus DNA; antivirus agent; hepatitis B surface antigen; immunoglobulin M; virus DNA, acute hepatitis B; chronic hepatitis B; coinfection; elastography; hepatitis B; history; human; Human immunodeficiency virus infection; incidence; liver transplantation; nuclear magnetic resonance imaging; pathogenesis; prevalence; Review; serology; shear wave elastography; vaccination; vibration controlled transient elastography; virology; virus examination; virus reactivation; adult; chronic hepatitis B; hepatitis B; Hepatitis B virus; liver cirrhosis; liver tumor, Adult; Antiviral Agents; DNA, Viral; Hepatitis B; Hepatitis B Surface Antigens; Hepatitis B virus; Hepatitis B, Chronic; Humans; Immunoglobulin M; Liver Cirrhosis; Liver Neoplasms
Επίσημο URL (Εκδότης):
DOI:
10.1016/S0140-6736(22)01468-4
Το ψηφιακό υλικό του τεκμηρίου δεν είναι διαθέσιμο.